Abatacept
- Generic Name
- Abatacept
- Brand Names
- Orencia
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 332348-12-6
- Unique Ingredient Identifier
- 7D0YB67S97
- Background
Abatacept is a soluble fusion protein, which links the extracellular domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) to the modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1). Structurally, abatacept is a glycosylated fusion protein with a MALDI-MS molecular weight of 92,300 Da and it is a homodimer of tw...
- Indication
Abatacept is indicated in adult patients for the treatment of moderately-to-severely active rheumatoid arthritis and for the treatment of active psoriatic arthritis. In patients two years of age and older, abatacept is also indicated for the treatment of moderately-to-severely active juvenile idiopathic arthritis.
...
- Associated Conditions
- Acute Graft-Versus-Host Disease (GVHD), Moderate to Severe Rheumatoid Arthritis, Polyarticular Juvenile Idiopathic Arthritis, Polyarticular juvenile rheumatoid arthritis, chronic or unspecified, Psoriatic Arthritis
- Associated Therapies
- -
Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response
- Conditions
- Interventions
- First Posted Date
- 2018-01-30
- Last Posted Date
- 2024-06-24
- Lead Sponsor
- University of Nebraska
- Target Recruit Count
- 400
- Registration Number
- NCT03414502
- Locations
- 🇺🇸
University of Nebraska Medical Center, Omaha, Nebraska, United States
Abatacept for the Treatment of Myositis-associated Interstitial Lung Disease
- Conditions
- Interventions
- First Posted Date
- 2017-07-12
- Last Posted Date
- 2023-06-01
- Lead Sponsor
- Rohit Aggarwal, MD
- Target Recruit Count
- 20
- Registration Number
- NCT03215927
- Locations
- 🇺🇸
University of Pittsburgh, Pittsburgh, Pennsylvania, United States
🇺🇸University of Colorado Anschutz Medical Campus, Denver, Colorado, United States
🇺🇸Cedars-Sinai Medical Center, Beverly Hills, California, United States
A Study to Evaluate Efficacy and Safety of Subcutaneous Abatacept With Steroid Treatment Compared to Steroid Treatment Alone in Adults With Giant Cell Arteritis (GCA)
- Conditions
- Interventions
- First Posted Date
- 2017-06-20
- Last Posted Date
- 2017-07-12
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT03192969
- Locations
- 🇬🇧
Local Institution, London, United Kingdom
A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs
- First Posted Date
- 2017-03-22
- Last Posted Date
- 2024-07-18
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 657
- Registration Number
- NCT03086343
- Locations
- 🇺🇸
SunValley Arthritis Center, Lt /ID# 154558, Peoria, Arizona, United States
🇺🇸AZ Arthritis & Rheum Research /ID# 156539, Sun City, Arizona, United States
🇺🇸CHI St. Vincent Medical Group /ID# 154561, Hot Springs, Arkansas, United States
APRIL (AbatacePt in Rheumatoid Arthritis-ILD)
- First Posted Date
- 2017-03-21
- Last Posted Date
- 2019-07-22
- Target Recruit Count
- 30
- Registration Number
- NCT03084419
- Locations
- 🇬🇧
Papworth Hospital, Cambridge, United Kingdom
🇬🇧Addenbrookes Hospital, Cambridge, United Kingdom
Abatacept for GVHD Prophylaxis After Hematopoietic Stem Cell Transplantation for Pediatric Sickle Cell Disease
- Conditions
- Interventions
- First Posted Date
- 2016-08-16
- Last Posted Date
- 2024-06-13
- Lead Sponsor
- Monica Bhatia
- Target Recruit Count
- 24
- Registration Number
- NCT02867800
- Locations
- 🇺🇸
North Carolina Cancer Hospital, Chapel Hill, North Carolina, United States
🇺🇸Columbia University Irving Medical Center, New York, New York, United States
🇺🇸Children's National Medical Center, Washington, District of Columbia, United States
Treatment Tapering in JIA With Inactive Disease
- Conditions
- Interventions
- First Posted Date
- 2016-07-21
- Last Posted Date
- 2021-04-01
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 62
- Registration Number
- NCT02840175
- Locations
- 🇫🇷
Necker Children's Hospital, Paris, France
Pharmacokinetics, Safety and Tolerability Study of Single Dose of Abatacept 125mg Administered Subcutaneously
- First Posted Date
- 2016-06-17
- Last Posted Date
- 2016-12-06
- Lead Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
- Target Recruit Count
- 22
- Registration Number
- NCT02805010
Abatacept Reversing Subclinical Inflammation as Measured by MRI in ACPA Positive Arthralgia
- First Posted Date
- 2016-05-20
- Last Posted Date
- 2020-03-10
- Lead Sponsor
- University of Erlangen-Nürnberg Medical School
- Target Recruit Count
- 98
- Registration Number
- NCT02778906
- Locations
- 🇩🇪
Charite Berlin, Berlin, Germany
🇩🇪Clinic Burghausen, Burghausen, Germany
🇩🇪University Clinic Erlangen, Erlangen, Germany
Inhibition of Co-Stimulation in Rheumatoid Arthritis
- First Posted Date
- 2016-01-11
- Last Posted Date
- 2016-01-12
- Lead Sponsor
- NHS Greater Glasgow and Clyde
- Target Recruit Count
- 25
- Registration Number
- NCT02652273
- Locations
- 🇬🇧
NHS Greater Glasgow and Clyde, Glasgow, United Kingdom
🇬🇧Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.